Richard W Joseph

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/527528/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	13.7	3,077
3	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	13.7	1,728
4	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
5	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	30.7	900
6	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
7	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	1.6	627
8	<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. Cancer, 2012, 118, 4014-4023.	4.1	589
9	Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	1.6	528
10	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2018, 36, 1668-1674.	1.6	360
11	High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 2018, 553, 347-350.	27.8	269
12	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clinical Cancer Research, 2012, 18, 5329-5340.	7.0	266
13	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	7.0	222
14	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
15	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology, 2015, 67, 4-17.	2.2	180
16	Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 2012, 10, 23.	5.5	179
17	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 2017, 75, 47-55.	2.8	145
18	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research, 2015, 3, 1303-1307.	3.4	135

#	Article	IF	CITATIONS
19	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with lowâ€risk clear cell renal cell carcinoma. Cancer, 2014, 120, 1059-1067.	4.1	129
20	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 5250-5260.	7.0	116
21	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. Journal of Urology, 2016, 195, 180-187.	0.4	113
22	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. Journal of Immunotherapy, 2012, 35, 66-72.	2.4	111
23	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. Cancer Immunology Research, 2013, 1, 373-377.	3.4	100
24	Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy. Cancer Immunology Research, 2015, 3, 18-22.	3.4	100
25	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
26	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	4.9	76
27	High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene, 2016, 35, 1565-1574.	5.9	72
28	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
29	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Modern Pathology, 2016, 29, 34-42.	5.5	55
30	A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Research, 2012, 22, 294-301.	1.2	53
31	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. European Urology, 2017, 71, 979-985.	1.9	52
32	Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. Clinical Cancer Research, 2011, 17, 4882-4891.	7.0	48
33	The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Frontiers in Oncology, 2017, 7, 121.	2.8	48
34	Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. Surgical Oncology, 2018, 27, 11-17.	1.6	48
35	ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. BMC Urology, 2014, 14, 14.	1.4	47
36	Evaluation of the association of prostate cancerâ€specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psycho-Oncology, 2013, 22, 1328-1335.	2.3	42

#	Article	IF	CITATIONS
37	Loss of PBRM1 and BAP1 expression is less common in non–clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 23.e9-23.e14.	1.6	40
38	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus, 2016, 2, 204-209.	3.1	40
39	Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research, 2017, 5, 357-362.	3.4	40
40	Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences. Annals of Surgical Oncology, 2015, 22, 4060-4066.	1.5	39
41	Steroid hormone influence on melanomagenesis. Molecular and Cellular Endocrinology, 2015, 417, 94-102.	3.2	38
42	Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2013, 1, 378-385.	3.4	37
43	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3706-3713.	1.6	34
44	Vitamin D receptor upregulation in alloreactive human T cells. Human Immunology, 2012, 73, 693-698.	2.4	33
45	Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case–control studies. Prostate Cancer and Prostatic Diseases, 2013, 16, 352-356.	3.9	33
46	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2014, 8, 775.	4.3	32
47	c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Research, 2014, 24, 617-620.	1.2	30
48	Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. European Urology, 2014, 66, 929-935.	1.9	29
49	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. Cancer, 2018, 124, 537-545.	4.1	27
50	Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS ONE, 2020, 15, e0230306.	2.5	27
51	High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. American Journal of Hematology, 2011, 86, 954-956.	4.1	26
52	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urology, 2017, 17, 19.	1.4	26
53	Age-period-cohort Analysis of Renal Cell Carcinoma in United States Adults. Urology, 2013, 82, 43-47.	1.0	25
54	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Molecular Cancer Therapeutics, 2015, 14, 1962-1971.	4.1	25

#	Article	IF	CITATIONS
55	Three Hundred Consecutive Emergent Celiotomies in General Surgery Patients. Annals of Surgery, 2002, 235, 681-689.	4.2	24
56	Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. Journal of Immunotherapy, 2012, 35, 711-715.	2.4	24
57	Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation. Rare Tumors, 2015, 7, 133-135.	0.6	22
58	Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. Frontiers in Oncology, 2018, 8, 71.	2.8	22
59	Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass. Journal of Clinical Oncology, 2015, 33, e74-e76.	1.6	20
60	Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Research, 2016, 26, 409-412.	1.2	20
61	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunology Research, 2016, 4, 569-573.	3.4	20
62	Patient-derived tumor xenograft models for melanoma drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 895-906.	5.0	20
63	Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. Journal of Kidney Cancer and VHL, 2018, 5, 15-18.	1.0	20
64	An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer. PLoS ONE, 2013, 8, e79298.	2.5	18
65	Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma. Carcinogenesis, 2014, 35, 822-827.	2.8	18
66	Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. Journal of Translational Medicine, 2016, 14, 198.	4.4	17
67	Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. Quality of Life Research, 2020, 29, 2651-2660.	3.1	17
68	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 142-148.	1.6	16
69	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of Immunotherapy, 2017, 40, 334-340.	2.4	16
70	New-onset insulin-dependent diabetes due to nivolumab. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.5	14
71	Desmoplastic melanoma: a brief review and the efficacy of immunotherapy. Expert Review of Anticancer Therapy, 2019, 19, 205-207.	2.4	13
72	Whole Exome Sequencing of a Patient with Metastatic Hidradenocarcinoma and Review of the Literature. Rare Tumors, 2015, 7, 29-33.	0.6	11

#	Article	IF	CITATIONS
73	Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article Urologic Oncology: Seminars and Original Investigations, 2015, 33, 68.e17-68.e23.	1.6	10
74	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS ONE, 2015, 10, e0132831.	2.5	9
75	A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 196-202.e1.	1.9	9
76	Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. The Journal of Supportive Oncology, 2008, 6, 361-72.	2.3	9
77	Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. Rare Tumors, 2017, 9, 50-53.	0.6	8
78	Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Management, 2017, 4, 143-145.	0.5	8
79	Ultrathin primary is a marker for worse prognosis in lymph node–positive cutaneous melanoma. Cancer, 2013, 119, 1860-1867.	4.1	7
80	Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. European Urology Focus, 2016, 2, 608-615.	3.1	7
81	Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics, 2020, 23, 132-138.	2.1	6
82	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS ONE, 2021, 16, e0248097.	2.5	5
83	Efficacy of immunotherapy for metastatic mucosal melanoma. Immunotherapy, 2016, 8, 843-845.	2.0	3
84	Drug-associated vasculitis occurring after treatment with pembrolizumab. Rheumatology, 2019, 58, 1501-1503.	1.9	3
85	Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy, 2018, 10, 1361-1369.	2.0	2
86	Title is missing!. , 2020, 15, e0230306.		0
87	Title is missing!. , 2020, 15, e0230306.		0
88	Title is missing!. , 2020, 15, e0230306.		0
89	Title is missing!. , 2020, 15, e0230306.		0